Pacira BioSciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.3%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$754Mnext fiscal year
Monitoring Framework
Key Performance Indicators
EXPAREL Net Product Sales Quarterly143.3MTarget: 600000000 to 620000000
Total Revenue Quarterly177.4MTarget: 745000000 to 770000000
ZILRETTA Net Product Sales Quarterly26.8MTarget: In line with 2025
iovera° Net Product Sales Quarterly6.2M
Watch Items
- NOPAIN Act Implementation and Reimbursement CatalystTrigger: Medicare outpatient and ASC reimbursement expansionAction: Monitor hospital and ASC adoption rates and commercial payer coverage expansion beyond the 110 million covered lives baseline.
- PCRX-201 Phase 2 ASCEND Study ReadoutTrigger: Topline 52-week data from Part A in knee osteoarthritisAction: Evaluate efficacy, safety, and durability of the locally administered gene therapy candidate by late 2026.
- ZILRETTA Phase 3 Registrational Study in Shoulder OsteoarthritisTrigger: Topline clinical trial readoutAction: Assess potential label expansion opportunities and commercial synergy with the J&J MedTech co-promotion agreement.
- Post-AGM Board Restructuring and Activist PressureTrigger: Thomas Wiggans appointment and committee restructuringAction: Track execution of the 5x30 strategy and capital allocation, including the remaining $100 million share repurchase authorization.
Research as of 19 Jun 2026